Potential Prophylactic Treatments for COVID-19

The World Health Organization declared the SARS-CoV-2 outbreak a Public Health Emergency of International Concern at the end of January 2020 and a pandemic two months later. The virus primarily spreads between humans via respiratory droplets, and is the causative agent of Coronavirus Disease 2019 (C...

Full description

Bibliographic Details
Main Authors: Noam Ben-Zuk, Ido-David Dechtman, Itai Henn, Libby Weiss, Amichay Afriat, Esther Krasner, Yoav Gal
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Viruses
Subjects:
Online Access:https://www.mdpi.com/1999-4915/13/7/1292
id doaj-d9cad27cb4ff41049c4e15a2204448d3
record_format Article
spelling doaj-d9cad27cb4ff41049c4e15a2204448d32021-07-23T14:11:27ZengMDPI AGViruses1999-49152021-07-01131292129210.3390/v13071292Potential Prophylactic Treatments for COVID-19Noam Ben-Zuk0Ido-David Dechtman1Itai Henn2Libby Weiss3Amichay Afriat4Esther Krasner5Yoav Gal6Chemical, Biological, Radiological and Nuclear Defense Division, Ministry of Defense, HaKirya, Tel-Aviv 61909, IsraelThe Israel Defense Force Medical Corps, Tel Hashomer, Military Post 02149, IsraelChemical, Biological, Radiological and Nuclear Defense Division, Ministry of Defense, HaKirya, Tel-Aviv 61909, IsraelChemical, Biological, Radiological and Nuclear Defense Division, Ministry of Defense, HaKirya, Tel-Aviv 61909, IsraelDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 7610001, IsraelChemical, Biological, Radiological and Nuclear Defense Division, Ministry of Defense, HaKirya, Tel-Aviv 61909, IsraelChemical, Biological, Radiological and Nuclear Defense Division, Ministry of Defense, HaKirya, Tel-Aviv 61909, IsraelThe World Health Organization declared the SARS-CoV-2 outbreak a Public Health Emergency of International Concern at the end of January 2020 and a pandemic two months later. The virus primarily spreads between humans via respiratory droplets, and is the causative agent of Coronavirus Disease 2019 (COVID-19), which can vary in severity, from asymptomatic or mild disease (the vast majority of the cases) to respiratory failure, multi-organ failure, and death. Recently, several vaccines were approved for emergency use against SARS-CoV-2. However, their worldwide availability is acutely limited, and therefore, SARS-CoV-2 is still expected to cause significant morbidity and mortality in the upcoming year. Hence, additional countermeasures are needed, particularly pharmaceutical drugs that are widely accessible, safe, scalable, and affordable. In this comprehensive review, we target the prophylactic arena, focusing on small-molecule candidates. In order to consolidate a potential list of such medications, which were categorized as either antivirals, repurposed drugs, or miscellaneous, a thorough screening for relevant clinical trials was conducted. A brief molecular and/or clinical background is provided for each potential drug, rationalizing its prophylactic use as an antiviral or inflammatory modulator. Drug safety profiles are discussed, and current medical indications and research status regarding their relevance to COVID-19 are shortly reviewed. In the near future, a significant body of information regarding the effectiveness of drugs being clinically studied for COVID-19 is expected to accumulate, in addition to information regarding the efficacy of prophylactic treatments.https://www.mdpi.com/1999-4915/13/7/1292SARS-CoV-2COVID-19treatmentprophylaxispre-exposurepost-exposure
collection DOAJ
language English
format Article
sources DOAJ
author Noam Ben-Zuk
Ido-David Dechtman
Itai Henn
Libby Weiss
Amichay Afriat
Esther Krasner
Yoav Gal
spellingShingle Noam Ben-Zuk
Ido-David Dechtman
Itai Henn
Libby Weiss
Amichay Afriat
Esther Krasner
Yoav Gal
Potential Prophylactic Treatments for COVID-19
Viruses
SARS-CoV-2
COVID-19
treatment
prophylaxis
pre-exposure
post-exposure
author_facet Noam Ben-Zuk
Ido-David Dechtman
Itai Henn
Libby Weiss
Amichay Afriat
Esther Krasner
Yoav Gal
author_sort Noam Ben-Zuk
title Potential Prophylactic Treatments for COVID-19
title_short Potential Prophylactic Treatments for COVID-19
title_full Potential Prophylactic Treatments for COVID-19
title_fullStr Potential Prophylactic Treatments for COVID-19
title_full_unstemmed Potential Prophylactic Treatments for COVID-19
title_sort potential prophylactic treatments for covid-19
publisher MDPI AG
series Viruses
issn 1999-4915
publishDate 2021-07-01
description The World Health Organization declared the SARS-CoV-2 outbreak a Public Health Emergency of International Concern at the end of January 2020 and a pandemic two months later. The virus primarily spreads between humans via respiratory droplets, and is the causative agent of Coronavirus Disease 2019 (COVID-19), which can vary in severity, from asymptomatic or mild disease (the vast majority of the cases) to respiratory failure, multi-organ failure, and death. Recently, several vaccines were approved for emergency use against SARS-CoV-2. However, their worldwide availability is acutely limited, and therefore, SARS-CoV-2 is still expected to cause significant morbidity and mortality in the upcoming year. Hence, additional countermeasures are needed, particularly pharmaceutical drugs that are widely accessible, safe, scalable, and affordable. In this comprehensive review, we target the prophylactic arena, focusing on small-molecule candidates. In order to consolidate a potential list of such medications, which were categorized as either antivirals, repurposed drugs, or miscellaneous, a thorough screening for relevant clinical trials was conducted. A brief molecular and/or clinical background is provided for each potential drug, rationalizing its prophylactic use as an antiviral or inflammatory modulator. Drug safety profiles are discussed, and current medical indications and research status regarding their relevance to COVID-19 are shortly reviewed. In the near future, a significant body of information regarding the effectiveness of drugs being clinically studied for COVID-19 is expected to accumulate, in addition to information regarding the efficacy of prophylactic treatments.
topic SARS-CoV-2
COVID-19
treatment
prophylaxis
pre-exposure
post-exposure
url https://www.mdpi.com/1999-4915/13/7/1292
work_keys_str_mv AT noambenzuk potentialprophylactictreatmentsforcovid19
AT idodaviddechtman potentialprophylactictreatmentsforcovid19
AT itaihenn potentialprophylactictreatmentsforcovid19
AT libbyweiss potentialprophylactictreatmentsforcovid19
AT amichayafriat potentialprophylactictreatmentsforcovid19
AT estherkrasner potentialprophylactictreatmentsforcovid19
AT yoavgal potentialprophylactictreatmentsforcovid19
_version_ 1721285454795374592